Development of a universal CTL-based vaccine for influenza

Bioengineered

Volumn 4, Issue 6, 2013, Pages

  Cargnelutti, Diego E ^a   Sánchez, María V ^a   Mattion, Nora M ^a   Scodeller, Eduardo A ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Adjuvants; Cellular immunity; Cross presentation; Cytotoxic T lymphocytes; Influenza vaccines; Recombinant antigen

Indexed keywords

CYTOTOXIC T LYMPHOCYTE BASED VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; PROTEIN M2; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; RECOMBINANT ANTIGEN;

CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DISEASE CONTROL; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA; PROCESS DEVELOPMENT; REVIEW; VACCINATION; ADJUVANTS; ANIMAL; CROSS PRESENTATION; CROSS REACTION; CYTOTOXIC-T-LYMPHOCYTES; DISEASE MODEL; GENE TRANSFER; GENE VECTOR; IMMUNOLOGY; INFLUENZA VIRUS A; VIROLOGY;

ADJUVANTS; CELLULAR IMMUNITY; CROSS-PRESENTATION; CYTOTOXIC-T-LYMPHOCYTES; INFLUENZA VACCINES; RECOMBINANT ANTIGEN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CROSS REACTIONS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 84887541877     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: 10.4161/bioe.23573     Document Type: Review

References (70)

1. Osterhaus A, Fouchier R, Rimmelzwaan G. Towards universal influenza vaccines? Philos Trans R Soc Lond B Biol Sci 2011; 366:2766-2773;PMID:21893539;http://dx.doi.org/10.1098/rstb.2011.0102.
2. Dormitzer PR, Tsai T F, Del Giudice G. New technologies for influenza vaccines. Hum Vaccin Immunother 2012; 8:45-58;PMID:22251994.
3. Osterholm M T, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44;PMID:22032844;http://dx.doi.org/10.1016/S1473-3099(11)70295-X.
4. Quan FS, Compans RW, Kang SM. Oral vaccination with inactivated influenza vaccine induces cross-protective immunity. Vaccine 2012; 30:180-188;PMID:22107852;http://dx.doi.org/10.1016/j.vac-cine.2011.11.028.
5. Okamoto S, Matsuoka S, Takenaka N, Haredy AM, Tanimoto T, Gomi Y, et al. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection. Clin Vaccine Immunol 2012; 19:979-990;PMID:22552600;http://dx.doi.org/10.1128/CVI.00016-12.
6. Dhont PA, Albert A, Brenders P, Podwapinska A, Pollet A, Scheveneels D, et al. Acceptability of Intanza® 15 μg intradermal influenza vaccine in Belgium during the 2010-2011 influenza season. Adv Ther 2012; 29:562-577;PMID:22678831;http://dx.doi.org/10.1007/s12325-012-0025-9.
7. Kang SM, Song JM, Kim YC. Microneedle and muco-sal delivery of influenza vaccines. Expert Rev Vaccines 2012; 11:547-560;PMID:22697052;http://dx.doi.org/10.1586/erv.12.25.
8. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 2012; 30:4341-4348;PMID:22682289;http://dx.doi.org/10.1016/j.vac-cine.2011.09.061.
9. Scheifele DW, Ward BJ, Dionne M, Vanderkooi OG, Loeb M, Coleman BL, et al.; PHAC/CIHR Influenza Research Network (PCIRN). Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal tri-valent influenza vaccines in adults: results of a randomized, controlled trial. Vaccine 2012; 30:4728-4732;PMID:22652402;http://dx.doi.org/10.1016/j.vac-cine.2012.05.029.
10. Cox RJ, Pedersen G, Madhun AS, Svindland S, Sævik M, Breakwell L, et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 2011; 29:8049-8059;PMID:21864624;http://dx.doi.org/10.1016/j.vac-cine.2011.08.042.
11. Budimir N, Huckriede A, Meijerhof T, Boon L, Gostick E, Price DA, et al. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. PLoS One 2012; 7:e30898;PMID:22303469;http://dx.doi.org/10.1371/journal.pone.0030898.
12. Furuya Y, Regner M, Lobigs M, Koskinen A, Müllbacher A, Alsharifi M. Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations. J Gen Virol 2010; 91:1450-1460;PMID:20147516;http://dx.doi.org/10.1099/vir.0.018168-0.
13. Hessel A, Schwendinger M, Holzer G W, Orlinger KK, Coulibaly S, Savidis-Dacho H, et al. Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS One 2011; 6:e16247;PMID:21283631;http://dx.doi.org/10.1371/journal.pone.0016247.
14. Schwartz JA, Buonocore L, Suguitan A Jr., Hunter M, Marx PA, Subbarao K, et al. Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. J Virol 2011; 85:4602-4605;PMID:21325423;http://dx.doi.org/10.1128/JVI.02491-10.
15. Steitz J, Barlow PG, Hossain J, Kim E, Okada K, Kenniston T, et al. A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice. PLoS One 2010; 5:e10492;PMID:20463955;http://dx.doi.org/10.1371/journal.pone.0010492.
16. Hossain MJ, Bourgeois M, Quan FS, Lipatov AS, Song JM, Chen LM, et al. Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza. Clin Vaccine Immunol 2011; 18:2010-2017;PMID:22030367;http://dx.doi.org/10.1128/CVI.05206-11.
17. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733-7739;PMID:21835220;http://dx.doi.org/10.1016/j.vac-cine.2011.07.128.
18. Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, et al. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J Virol 2011; 5:1246-1256;PMID:21084473;http://dx.doi.org/10.1128/JVI.02107-10.
19. Taylor DN, Treanor JJ, Sheldon EA, Johnson C, Umlauf S, Song L, et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 2012; 30:5761-5769;PMID:22796139;http://dx.doi.org/10.1016/j.vaccine.2012.06.086.
20. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, et al.; VRC 306 Study Team. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11:916-924;PMID:21975270;http://dx.doi.org/10.1016/S1473-3099(11)70240-7.
21. Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, et al. Safety and immuno-genicity of multimeric-001--a novel universal influenza vaccine. J Clin Immunol 2012; 32:595-603;PMID:22318394;http://dx.doi.org/10.1007/s10875-011-9632-5.
22. Roose K, Fiers W, Saelens X. Pandemic preparedness: toward a universal influenza vaccine. Drug News Perspect 2009; 22:80-92;PMID:19330167;http://dx.doi.org/10.1358/dnp.2009.22.2.1334451.
23. Yewdell J W. Viva la revolución: rethinking influenza a virus antigenic drift. Curr Opin Virol 2011; 1:177-83;PMID:22034587;http://dx.doi.org/10.1016/j.coviro.2011.05.005.
24. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850-856;PMID:21798894;http://dx.doi.org/10.1126/sci-ence.1205669.
25. Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 2010; 107:18979-18984;PMID:20956293;http://dx.doi.org/10.1073/pnas.1013387107.
26. Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009; 8:499-508;PMID:19348565;http://dx.doi.org/10.1586/erv.09.6.
27. Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, et al. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS One 2011; 6:e27953;PMID:22140491;http://dx.doi.org/10.1371/journal.pone.0027953.
28. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011; 186:1022-1031;PMID:21169548;http://dx.doi.org/10.4049/jimmunol.0902147.
29. Talbot HK, Rock MT, Johnson C, Tussey L, Kavita U, Shanker A, et al. Immunopotentiation of triva-lent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One 2010; 5:e14442;PMID:21203437;http://dx.doi.org/10.1371/journal.pone.0014442.
30. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, et al. Safety and immuno-genicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011; 29:5145-5152;PMID:21624416;http://dx.doi.org/10.1016/j.vaccine.2011.05.041.
31. Gilbert SC. T-cell-inducing vaccines - what's the future. Immunology 2012; 135:19-26;PMID:22044118;http://dx.doi.org/10.1111/j.1365-2567.2011.03517.x.
32. Mbawuike IN, Zhang Y, Couch RB. Control of muco-sal virus infection by influenza nucleoprotein-specific CD8+ cytotoxic T lymphocytes. Respir Res 2007; 8:44;PMID:17597533;http://dx.doi.org/10.1186/1465-9921-8-44.
33. Effros RB, Doherty PC, Gerhard W, Bennink J. Generation of both cross-reactive and virus-specific T-cell populations after immunization with sero-logically distinct influenza A viruses. J Exp Med 1977; 145:557-568;PMID:233901;http://dx.doi.org/10.1084/jem.145.3.557.
34. Yap KL, Ada GL, McKenzie I F. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 1978; 273:238-239;PMID:306072;http://dx.doi.org/10.1038/273238a0.
35. Wraith DC, Askonas BA. Induction of influenza A virus cross-reactive cytotoxic T cells by a nucleo-protein/haemagglutinin preparation. J Gen Virol 1985; 66:1327-1331;PMID:3874261;http://dx.doi.org/10.1099/0022-1317-66-6-1327.
36. Hurwitz JL, Hackett CJ, McAndrew EC, Gerhard W. Murine TH response to influenza virus: recognition of hemagglutinin, neuraminidase, matrix, and nucleopro-teins. J Immunol 1985; 134:1994-1998;PMID:3155776.
37. Yewdell J W, Bennink JR, Smith GL, Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1985; 82:1785-1789;PMID:3872457;http://dx.doi.org/10.1073/pnas.82.6.1785.
38. Taylor PM, Askonas BA. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology 1986; 58:417-420;PMID:2426185.
39. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309:13-17;PMID:6602294;http://dx.doi.org/10.1056/NEJM198307073090103.
40. Epstein SL. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 2006; 193:49-53;PMID:16323131;http://dx.doi.org/10.1086/498980.
41. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan G F. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 2008; 82:5161-5166;PMID:18353950;http://dx.doi.org/10.1128/JVI.02694-07.
42. Tite J P, Hughes-Jenkins C, O'Callaghan D, Dougan G, Russell SM, Gao XM, et al. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection. Immunology 1990; 71:202-207;PMID:2172156.
43. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-1749;PMID:8456302;http://dx.doi.org/10.1126/science.8456302.
44. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, Houser KV, et al. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 2010; 5:e13162;PMID:20976273;http://dx.doi.org/10.1371/journal.pone.0013162.
45. Zhou D, Wu TL, Lasaro MO, Latimer B P, Parzych EM, Bian A, et al. A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Mol Ther 2010; 18:2182-2189;PMID:20877342;http://dx.doi.org/10.1038/mt.2010.202.
46. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, et al. Potent CD8+ T-cell immunogenic-ity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011; 52:1-7;PMID:21148512;http://dx.doi.org/10.1093/cid/ciq015.
47. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA- NP+M1, in humans. Clin Infect Dis 2012; 55:19-25;PMID:22441650;http://dx.doi.org/10.1093/cid/cis327.
48. Ye Q, Krug RM, Tao YJ. The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA. Nature 2006; 444:1078-1082;PMID:17151603;http://dx.doi.org/10.1038/nature05379.
49. Guo L, Zheng M, Ding Y, Li D, Yang Z, Wang H, et al. Protection against multiple influenza A virus subtypes by intranasal administration of recombi-nant nucleoprotein. Arch Virol 2010; 155:1765-1775;PMID:20652335;http://dx.doi.org/10.1007/s00705-010-0756-3.
50. Thuengin K, Maneewatch S, Srimanote P, Songserm T, Tapchaisri P, Sookrung N, et al. Heterosubtypic immunity to influenza mediated by liposome adju-vanted H5N1 recombinant protein vaccines. Vaccine 2010; 28:6765-6777;PMID:20688037;http://dx.doi.org/10.1016/j.vaccine.2010.07.065.
51. Ebrahimi SM, Tebianian M, Aghaiypour K, Nili H, Mirjalili A. Prokaryotic expression and characterization of avian influenza A virus M2 gene as a candidate for universal recombinant vaccine against influenza A subtypes; specially H5N1 and H9N2. Mol Biol Rep 2010; 37:2909-2914;PMID:19809890;http://dx.doi.org/10.1007/s11033-009-9851-5.
52. Neefjes J, Sadaka C. Into the intracellular logistics of cross-presentation. Front Immunol 2012; 3:31;PMID:22566915;http://dx.doi.org/10.3389/fimmu.2012.00031.
53. Dresch C, Leverrier Y, Marvel J, Shortman K. Development of antigen cross-presentation capacity in dendritic cells. Trends Immunol 2012; 33:381-388;PMID:22677187;http://dx.doi.org/10.1016/j.it.2012.04.009.
54. Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, Goldsmith PK, et al. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J Immunol 2011; 186:2422-2429;PMID:21242525;http://dx.doi.org/10.4049/jimmu-nol.1002845.
55. Wilson NS, Yang B, Morelli AB, Koernig S, Yang A, Loeser S, et al. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol Cell Biol 2012; 90:540-552;PMID:21894173;http://dx.doi.org/10.1038/icb.2011.71.
56. Morelli AB, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol 2012; 61:935-943;PMID:22442293;http://dx.doi.org/10.1099/jmm.0.040857-0.
57. McBurney WT, Lendemans DG, Myschik J, Hennessy T, Rades T, Hook S. In vivo activity of cationic immune stimulating complexes (PLUSCOMs). Vaccine 2008; 26:4549-4556;PMID:18585421;http://dx.doi.org/10.1016/j.vaccine.2008.06.024.
58. Coulter A, Harris R, Davis R, Drane D, Cox J, Ryan D, et al. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine 2003; 21:946-949;PMID:12547607;http://dx.doi.org/10.1016/S0264-410X(02)00545-5.
59. Wee JL, Scheerlinck J P, Snibson KJ, Edwards S, Pearse M, Quinn C, et al. Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing. Mucosal Immunol 2008; 1:489-496;PMID:19079216;http://dx.doi.org/10.1038/mi.2008.59.
60. Sambhara S, Kurichh A, Miranda R, Tumpey T, Rowe T, Renshaw M, et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cyto-toxic T-lymphocyte and macrophage function. Cell Immunol 2001; 211:143-153;PMID:11591118;http://dx.doi.org/10.1006/cimm.2001.1835.
61. Ennis FA, Cruz J, Jameson J, Klein M, Burt D, Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 1999; 259:256-261;PMID:10388649;http://dx.doi.org/10.1006/viro.1999.9765.
62. Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, Sutter G, Beyer WE, Maher D, et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 2000; 19:1180-1187;PMID:11137255;http://dx.doi.org/10.1016/S0264-410X(00)00310-8.
63. Cargnelutti DE, Sanchez MV, Alvarez P, Boado L, Glikmann G, Mattion N, et al. Improved immune response to recombinant influenza nucleoprotein formulated with ISCOMATRIX. J Microbiol Biotechnol 2012; 22:416-421;PMID:22450799;http://dx.doi.org/10.4014/jmb.1106.06021.
64. Lamere MW, Moquin A, Lee FE, Misra RS, Blair PJ, Haynes L, et al. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol 2011; 85:5027-5035;PMID:21367900;http://dx.doi.org/10.1128/JVI.00150-11.
65. LaMere MW, Lam HT, Moquin A, Haynes L, Lund FE, Randall TD, et al. Contributions of antinucleopro-tein IgG to heterosubtypic immunity against influenza virus. J Immunol 2011; 186:4331-4339;PMID:21357542;http://dx.doi.org/10.4049/jimmunol.1003057.
66. Savard C, Guérin A, Drouin K, Bolduc M, Laliberté-Gagné ME, Dumas MC, et al. Improvement of the trivalent inactivated flu vaccine using PapMV nanopar-ticles. PLoS One 2011; 6:e21522;PMID:21747909;http://dx.doi.org/10.1371/journal.pone.0021522.
67. Duthie MS, Raman VS, Piazza FM, Reed SG. The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine 2012; 30:134-141;PMID:22085553;http://dx.doi.org/10.1016/j.vac-cine.2011.11.005.
68. Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, Fokkink RG, et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011; 118:6836-6844;PMID:21967977;http://dx.doi.org/10.1182/blood-2011-07-367615.
69. Nembrini C, Stano A, Dane KY, Ballester M, van der Vlies AJ, Marsland BJ, et al. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A 2011; 108:E989-E997;PMID:21969597;http://dx.doi.org/10.1073/pnas.1104264108.
70. Foged C, Hansen J, Agger EM. License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. Eur J Pharm Sci 2012; 45:482-491;PMID:21888971;http://dx.doi.org/10.1016/j.ejps.2011.08.016.